Aberrant Splicing Candidates as Potential Neoantigen Expression in High-grade Glioma

Patients with high grade gliomas (HGG) face considerable treatment challenges. Comprehensive genetic and immune system research is needed to find new therapeutic options. One form of therapy that is promising for HGG patients is CAR T cell therapy. CAR T cell therapy is a type of treatment in which a patient’s T cells, a type of immune cell, are collected from a patient’s blood. In the laboratory, the gene for a special receptor that can bind to a patient’s cancer cells is added to the T cells. The special receptor is called a chimeric antigen receptor (CAR). This change causes the T cells so they will attack the tumor itself. Researchers will leverage large-scale datasets such as the Pediatric Brain Tumor Atlas with state-of-the-art technologies to inform novel targets for CAR T-cell therapy. Ultimately, researchers hope to improve survival outcomes as a result of information gained through this project.